CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why Momentum in Corcept (CORT) Should Keep going
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company
Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal, showing promise for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial demonstrated a median progression-free survival of 6.5 months and a significant overall survival gain of 4.5 months with relacorilant. Relacorilant's lack of new safety issues and potential for wide use, combined with promising survival data, suggest strong market potential and likely FDA approval by 2026.
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Corcept Therapeutics Incorporated CORT announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR).
Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results
Corcept Therapeutics (NASDAQ:CORT) shares surged more than 85% after the company announced positive results from its Phase 3 ROSELLA trial, evaluating relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer, that will support regulatory applications in the US and Europe. The trial met its primary endpoint, demonstrating a 30% reduction in the risk of disease progression compared to nab-paclitaxel alone.
Corcept's ovarian cancer combination drug meets main goal in late-stage study
Corcept Therapeutics said on Monday its experimental ovarian cancer drug in combination with chemotherapy met the main goal of a late-stage trial.
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
Here is how Corcept Therapeutics (CORT) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings growth potential.
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
